Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14167250 | 0.79 | MCL1 (0.33) | KDM4EMCL1LMNA | |
| SCHEMBL23893129 | 0.79 | KDM4E (0.52) | KDM4ECYP2D6 | |
| SCHEMBL14950892 | 0.78 | KDM4E (0.38) | KDM4ECYP2D6 | |
| SCHEMBL8496986 | 0.78 | MCL1 (0.36) | KDM4EMCL1LMNA | |
| SCHEMBL14167272 | 0.77 | LMNA (0.41) | KDM4ECYP2D6MCL1LMNA | |
| SCHEMBL19026674 | 0.77 | KDM4E (0.50) | KDM4ECYP2D6MCL1 | |
| SCHEMBL20224633 | 0.76 | MCL1 (0.34) | MCL1LMNA | |
| SCHEMBL13544542 | 0.76 | KDM4E (0.48) | KDM4ECYP2D6MCL1LMNA | |
| SCHEMBL21094212 | 0.76 | MCL1 (0.34) | MCL1LMNA | |
| SCHEMBL13544816 | 0.76 | MCL1 (0.34) | MCL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2023-09-28 | — | — | US | disclosed |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2017-06-22 | — | — | US | disclosed |
| CN-1310629-A | Combined administration of ACAT and MMP inhibitors for the treatment of atherosclerotic lesions | WARNER LAMBERT CO (US) | 2001-08-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303514-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KDM4E 1863/4885CYP2D6 2791/4885MCL1 471/4885 |
| US-20170174653-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | KDM4E 1982/4885CYP2D6 2085/4885MCL1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.